New Deal
Jim Tananbaum
CEO at FORESITE CAPITAL MANAGEMENT LLC
Investor
Deal Bio
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
INSITRO
Alexandria Venture Investments
£116m
38 dealmakers
Kinnate Biopharma
Nextech Invest
£74m
9 dealmakers
Velosbio
Cormorant Asset Management
£105m
16 dealmakers
Gemini Therapeutics
Fs Development Corp
£166m
45 dealmakers
Merck & Co
£2,116m
55 dealmakers
Nurix Therapeutics
Bain Capital Life Sciences
£95m
10 dealmakers
QUANTUM-SI
Highcape Capital Acquisition Corp
£1,052m
37 dealmakers
BLACKROCK
£287m
27 dealmakers
SOMALOGIC
Janus Henderson Investors
£891m
63 dealmakers
Genomics
Oxford Sciences Innovation
£21m
14 dealmakers
Inscripta
Foresite Capital Management
£108m
8 dealmakers
Crossover Health
Perceptive Advisors
£121m
18 dealmakers
Generation Bio
Wellington Management
£83m
12 dealmakers
Tango Therapeutics
£257m
32 dealmakers
Eikon Therapeutics
The Column Group
£106m
6 dealmakers
HEALTHVERITY
Durable Capital Partners
£71m
Element Biosciences
Counterpoint Global - Morgan Stanley
£198m
Pardes Biosciences
Ecor1 Capital
£199m
Kriya Therapeutics
Woodline Partners
£72m
Mammoth Biosciences
Greenspring Associates
BIT.BIO
Charles River Laboratories International
£76m
Harel Group
£382m
21 dealmakers
Maze Therapeutics
Driehaus Capital
£139m
DNANEXUS
Northpond Ventures
£151m
30 dealmakers
Narya Capital
£220m
13 dealmakers
Immpact Bio
£81m
Odyssey Therapeutics
Svb Financial Group
£152m
ALUMIS
£204m
5 dealmakers